A prospective randomized comparative study of the effects of intranasal and transdermal 17 β-estradiol on postmenopausal symptoms and vaginal cytology

Journal of Postgraduate Medicine

Volumn 53, Issue 4, 2007, Pages 221-227

  Odabasi A R ^a   Yuksel H ^a   Demircan, S S ^a   Kacar D F ^a   Culhaci N ^a   Ozkara E E ^b  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b Kir ehir State Hospital   (Turkey)

Author keywords

Intranasal estradiol; Menopause rating scale; Transdermal estradiol; Vaginal maturation index; Vaginal progesterone

Indexed keywords

ESTRADIOL; PROGESTERONE;

ADULT; ARTICLE; ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENTAL CAPACITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; VAGINA CYTOLOGY; VASOMOTOR DISORDER;

EID: 37849001384     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.33966     Document Type: Article

References (32)

1. Bachmann GA. Menopausal vasomotor symptoms: A review of causes, effects and evidence-based treatment options. J Reprod Med 2005;50:155-65.
2. Ballagh SA. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med 2005;23:126-40.
3. Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertüngealp J, Gompel A, Graziottin A, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8-14.
4. Skouby SO, Barlow D, Samsioe G, Gompel A, Pines A, Al-Azzawi F, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy. Maturitas 2004;48:19-25.
5. Kupperman HS, Blatt MH, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953;13:688-703.
6. Marx P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 2004;47:47-54.
7. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Warram J. The metabolism of estradiol; oral compared to intravenous administration. J Steroid Biochem 1985;23:1065-70.
8. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915.
9. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
10. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
11. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-6.
12. Frenkel Y, Kopernik G, Lazer S, Tugendreich D, Zmira N, Oettinger M, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
13. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int J Fertil Menopausal Stud 1993;38:5-11.
14. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: Position statement of The North American Menopause Society. Menopause 2003;10:113-32.
15. Mattsson LA, Christiansen C, Colau JC, Palacios S, Kenemans P, Bergeron C, et al. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182:545-52.
16. Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos Y, et al. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: Randomised dose-response study. Aerodiol Study Group. Lancet 1999;353:1574-8.
17. Cicinelli E, de Ziegler D, Galantino P, Pinto V, Barba B, Morgese S, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: A 1-year prospective study. Am J Obstet Gynecol 2002;187:556-60.
18. de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000;15:149-58.
19. Alder EM. How to asses quality of life? Aspects of methodology. International Congress Series 2002;1229:31-7.
20. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes 2003;1:28.
21. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: Effects on menopause symptoms and bone markers. Maturitas 2003;44:S67-77.
22. Schneider HP, Rosemeier HP, Schnitker J, Gerbsch S, Turck R. Application and factor analysis of the menopause rating scale [MRS] in a post-marketing surveillance study of Climen. Maturitas 2000;37:113-24.
23. Dören M, Azzawi FA, Donnez J, Van der Mooren MJ, Villero J, Gompel A. Therapeutic value and long-term safety of pulsed estrogen therapy. Maturitas 2001;38:S23-30.
24. Lopes P, Merkus HM, Nauman J, Bruschi F, Foidart JM, Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000;96:906-12.
25. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-71.
26. Pelissier C, de Kervasdoue A, Chuong VT, Maugis EL, de Mouillac F, Breil MH, et al. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climacteric symptoms. Maturitas 2001;37:181-9.
27. Rozenbaum H, Chevallier O, Moyal M, Durand G, Perineau M, This P, et al. Efficacy and tolerability of pulsed estrogen therapy: A 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Climacteric 2002;5:249-58.
28. Gompel A, Bergeron C, Jondet M, Dhont M, Van der Mooren MJ, Toth KS, et al. Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year. Maturitas 2000;36:209-15.
29. Alder E. The Blatt-Kupperman menopausal index: A critique. Maturitas 1998;29:19-24.
30. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): Reliability of scores of menopausal complaints. Climacteric 2000;3:59-64.
31. Notelovitz M. Urogenital aging: Solutions in clinical practice. Int J Gynaecol Obstet 1997;59:S35-9.
32. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: A literature review. Menopause 2004;11:120-30.